Experimental drug cocktail takes on Hard-to-Treat cancers

NCT ID NCT07466160

Recruiting now Disease control Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing two experimental drugs, 7MW3711 and JS207, given together (with or without chemotherapy) in people with advanced solid tumors that have stopped responding to standard treatments. The trial has two phases: first, finding the safest dose, then checking how well the combination works. About 280 participants will take part, and the main focus is on safety and tumor control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 7MW3711 and JS207 (two experimental drugs) given together, sometimes with chemotherapy (cisplatin or carboplatin)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This is an early-phase (1b/2) trial, so the main goals are safety and dosing—not yet proof of effectiveness. The drugs may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Shanghai Chest Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200043, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.